29462-26-8

Usage

Uses

Used in Pharmaceutical Industry:
Methanone, (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(2-chlorophenyl)is used as an antineoplastic agent for its ability to inhibit the growth of various cancer cells, including breast, lung, and prostate cancer cells. Its potential therapeutic applications are currently being investigated for the treatment of cancer.
Used in Anti-inflammatory Applications:
Methanone, (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(2-chlorophenyl)is used as an anti-inflammatory agent due to its demonstrated anti-inflammatory and analgesic effects in preclinical studies. It may be utilized in the development of treatments for inflammatory diseases.

Upstream product

• 40018-25-5 2-Chlorobenzoyl acetonitrile 
• 108-94-1 cyclohexanone 

Downstream Products

• 29462-22-4 5-(2-chloro-phenyl)-1,3,6,7,8,9-hexahydro-benzo[4,5]thieno[2,3-e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS

The present invention relates to a series of compounds of formula (A) having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding

Novel allosteric enhancers of agonist binding to the rat adenosine A1 receptor are described. The lead compound for the new series was PD 81,723 ((2-amino-4,5-dimethyl-3-thienyl)[3-(trifluoromethyl)phenyl]methanone), a compound previously reported by Bruns and co-workers (Mol. Pharmacol. 1990, 38, 950-958). The 4,5-dimethyl group and the benzoyl moiety were targets for further modifications, leading to series of 4,5-dialkyl (12a-g), of tetrahydrobenzo (12h-u), and of tetrahydropyridine (13a-g) derivatives. A number of compounds, in particular 12b, 12e, 12j, 12n, and 12u, proved superior to PD 81,723. Their EC50 values for enhancing the binding of the adenosine A1 receptor agonist N6-cyclopentyladenosine to the receptor were lower, and/or their antagonistic activity on the adenosine A1 receptor was shown to be diminished.